Osteoarthritis – Drug Pipeline Analysis and Market Forecasts to 201619 May 2010 • by Natalie Aster
GlobalData, the industry analysis specialist, has released its latest research, “Osteoarthritis– Drug Pipeline Analysis and Market Forecasts to 2016” which provides key data, information and analysis on the osteoarthritis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with osteoarthritis, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the osteoarthritis market.
The Osteoarthritis Market is Forecast to Show Marginal Growth until 2016
GlobalData estimated the global osteoarthritis therapeutics market to be worth $5 billion in 2009. It is expected to grow to $5.5 billion with a compound annual growth rate (CAGR) of 1.5% by 2016. This growth is primarily attributed to the aging population resulting in a high incidence and prevalence of the disease, and also pipeline product launches such as SMC021 and PF-4383119. Globally, the US remains the largest market for osteoarthritis therapeutics, and was valued at $2.6 billion in 2009. It is forecast to grow at a CAGR of 1.6% over the next seven years to reach $2.9 billion by 2016.
Increase in Disease Population to Drive the Osteoarthritis Market
The prevalence rate for osteoarthritis globally was 10.1% or approximately 75.8 million people. It is expected to increase from 75.8 million in 2009 to 82 million in 2016. The main reason for this is the high incidence rate in the aging population. Osteoarthritis is mainly prevalent in elderly persons. A significant increase in osteoarthritis incidence has occurred over the past few years. In addition a rapid increase in the obese population will also contribute to the increase of the incidence of osteoarthritis.
Low Treatment Seeking Rate is a Major Barrier in the Osteoarthritis Market
The poor treatment seeking rate is one of the main barriers to the growth of the market. The early detection of osteoarthritis can improve patients’ quality of life but there is often a lack of awareness about the disease. Therefore, in 2009, the treated population was only slightly more than a quarter of the diseased population However, the treatment seeking population is expected to grow at a slow rate during the period from 2009 to 2016
The Current Treatment Options are Moderately Successful in Meeting the Market Demand
GlobalData has analyzed the current market landscape and found it to be strong. NSAIDs and Cox inhibitors drugs are the two main types of drugs which are used in the treatment of osteoarthritis. On the basis of the many approved drugs in various classes, such as NSAIDS, COX-2 inhibitors and opioid analgesics, the overall competition is strong. The drugs include celebrex, Hyalgan and Mobic. The market is currently dominated by NSAIDs. However, disease modifying drugs are currently being developed by researchers. The unmet need for osteoarthritis therapeutics is estimated to be high. There seems to be a major focus on the efficacy profile of drugs as the current drugs’ tolerability has been found to be relatively low. There is unmet need in terms of safety as well as efficacy for which technologically innovative products will be required to capture value. The pipeline has many emerging innovative therapies that are likely to increase the growth of the present market.
GlobalData is an industry analysis specialist, providing information, research and analysis products, and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.